High materiality7/10
Spyre Therapeutics price target raised to $100 from $80 at Wedbush
Why it may matterVerify against the original reporting
buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wedbush raises SYRE target to $100; current price $82.07; upside ~22%.
- Wedbush target $100; current $82.07; ~22% upside.
Key facts
- 01
Target: $318
- 02
Posted price: $277.3
- 03
Analyst firm: Bernstein
- 04
Analyst: Douglas Harned
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.